home All News open_in_new Full Article

AstraZeneca: Krebsmedikamente treiben Wachstum – KI und Biotech stärken Pipeline

- AstraZeneca punktet 2025 mit starker Onkologie-Sparte, wachsender Pipeline und soliden Margen. KI-Integration soll F&E beschleunigen – Aktie im Aufwind.


today 8 h. ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Technology
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Society
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Politics
attach_file Society
attach_file Other
attach_file Other


ID: 4065406175
Add Watch Country

arrow_drop_down